Sildenafil Tablet, Film Coated
Product Images NDC 50090-5325

11 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 50090-5325). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafilchemicalstructure (Sildenafilchemicalstructure)

Sildenafilchemicalstructure (Sildenafilchemicalstructure)
Chemical structure diagram of Sildenafil. The depiction shows the molecular framework with labeled functional groups and rings characteristic of Sildenafil's chemical composition.*
FDA Label Image

Sildenafilfig1 (Sildenafilfig1)

Sildenafilfig1 (Sildenafilfig1)
A line graph depicting the change in systolic blood pressure (SBP) in mmHg over 8 hours post dose. Two data series are shown: one for Doxazosin plus Placebo and the other for Doxazosin plus Sildenafil 25 mg. The graph illustrates observed blood pressure changes over time for these treatments.*
FDA Label Image

Sildenafilfig2 (Sildenafilfig2)

Sildenafilfig2 (Sildenafilfig2)
A line graph showing change in systolic blood pressure (SBP) in mmHg over 8 hours post dose. Two data series are compared: Doxazosin with Placebo and Doxazosin with Sildenafil 25 mg. The graph tracks SBP changes from 0 to 8 hours after dosing, depicting differences between the two treatment combinations.*
FDA Label Image

Sildenafilfig3 (Sildenafilfig3)

Sildenafilfig3 (Sildenafilfig3)
A line graph depicting change in systolic blood pressure (SBP) in mmHg over time (hours) post dose. It compares two treatments: Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg, with data points marked by solid and open circles respectively, showing trends in blood pressure changes for up to 8 hours after dosing.*
FDA Label Image

Sildenafilfig4 (Sildenafilfig4)

Sildenafilfig4 (Sildenafilfig4)
A line graph showing the change in mmHg over time (hours) after dosing with two treatment groups: Doxazosin combined with Sildenafil 100 mg and Doxazosin combined with Placebo. The x-axis represents time after dosing in hours, and the y-axis represents mmHg values, ranging from -50 to 40. The graph compares blood pressure effects over an 8-hour period.*
FDA Label Image

Sildenafilfig5 (Sildenafilfig5)

Sildenafilfig5 (Sildenafilfig5)
A line graph showing plasma concentration (ng/mL) over time post dose (hours) for a Commercial Tablet treatment. The graph plots plasma concentration on the vertical axis and time from 0 to 24 hours on the horizontal axis, with a peak concentration near 1 hour post dose followed by a gradual decline to near zero by 24 hours.*
FDA Label Image

Sildenafilfog6a (Sildenafilfog6a)

Sildenafilfog6a (Sildenafilfog6a)
A bar chart showing the percentage distribution of patients at an endpoint across different categories labeled 0 to 5 on the horizontal axis. Each category displays multiple bars representing different groups or values indicated by a legend, with varying heights illustrating the proportion of patients in each group.*
FDA Label Image

Sildenafilfog6b (Sildenafilfog6b)

Sildenafilfog6b (Sildenafilfog6b)
A bar chart showing the percentage of patients at endpoint across categories 0 to 5 on the x-axis. The y-axis represents the percentage of patients, ranging from 0 to 80%. Each category includes multiple bars corresponding to values 0 to 5, as indicated in the legend on the right. The chart visually compares patient distribution across these groups.*
FDA Label Image

Sildenafilfig7 (Sildenafilfig7)

Sildenafilfig7 (Sildenafilfig7)
A bar chart showing the percentage of patients reporting improvement across different treatment groups including Placebo and Sildenafil Tablets at doses of 25 mg, 50 mg, and 100 mg. The chart indicates increasing patient improvement percentages with higher Sildenafil doses, with Placebo at 24%, 25 mg at 63%, 50 mg at 74%, and 100 mg at 82%.*
FDA Label Image
FDA Label Image

Label Image (Lbl500905325)

Label Image (Lbl500905325)
Sildenafil 100 mg film-coated tablets in a carton labeled by A-S Medication Solutions. The label states each film-coated tablet contains sildenafil citrate USP equivalent to 100 mg of sildenafil. Storage instructions specify to keep at 59 to 77 degrees Fahrenheit. The package contains 10 tablets, and includes the NDC 50090-5325-0 and product number 6804-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.